A new analysis suggests that people with type 2 diabetes who use GLP-1 medications like Ozempic, Trulicity or Victoza may be ...

Ozempic can be beneficial for a lot of people, however, some people should avoid it. Read on to know why the drug is not for ...

GLP-1 RAs probably have little or no effect on risk for thyroid cancer, pancreatic cancer, breast cancer, or kidney cancer.

Alzheimer's trials testing Novo Nordisk’s blockbuster GLP-1 drug semaglutide, despite their failure, underscore a shift to ...

Ozempic one of the most sought-after drugs across the world for its Type 2 Diabetes and weight loss treatment will be available in India at a starting weekly dose of 025 mg priced at INR 2200 ...

Step aside, semaglutide—retatrutide is showing the most impressive weight loss results of any obesity drug to date.

The team wanted to know whether these medications change someone’s risk of developing any of the 13 cancers linked to obesity ...

The executives of the companies say by pairing weight-loss drugs such as semaglutide (Wegovy) and tirzepatide (Mounjaro) with ...

Adults with type 2 diabetes or overweight or obesity who received GLP-1s do not have increased risk for obesity-related ...

Could popular GLP-1 drugs used to treat diabetes and obesity increase cancer risk? A large, new study suggests they likely do ...

A systematic review and meta-analysis evaluated the risk for obesity-related cancer associated with glucagon-like peptide-1 receptor agonists (GLP-1RAs) in patients with type 2 diabetes (T2D) or ...

A new review of nearly 100,000 participants suggests that glucagon-like peptide-1 receptor agonists (GLP-1RAs), popular ...